The hearing was supposed to focus on the Trump administration’s 2026 budget request, but instead covered a wide range of other FDA issues currently in the political spotlight. The FDA’s budget was not mentioned in the president’s preliminary spending package,

The Food and Drug Administration (FDA) announced plans to significantly curtail people’s access to Covid-19 vaccines.

The FDA may limit annual COVID-19 boosters to high-risk groups unless clinical trials prove benefits for healthy adults under 65. Pfizer is reviewing the plan, while officials call for more evidence on booster effectiveness.

Seven weeks into his job as FDA commissioner, Marty Makary, MD, MPH, held his own answering a barrage of sometimes acrimonious questions from Senators about agency staffing cuts, limits on COVID boosters, and more.

The FDA will encourage new clinical trials on the widely used vaccines before approving them for children and healthy adults. The requirements could cost drugmakers tens of millions of dollars and are likely to leave boosters largely out of reach for hundreds of millions of Americans this fall.

The FDA’s recent activities regarding Covid-19 vaccines stray far from the well-established standards of vaccine regulatory processes.

"With the COVID pandemic behind us, it is time to adopt a common-sense approach to COVID policy," a spokesperson for the FDA tells Rolling Stone. "Healthy individuals aged six mon

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels about heart inflammation.

As the Trump administration’s FDA moves to limit approval for COVID-19 booster shots, millions of Americans under 65 may find themselves without access this fall. However, until Friday, there’s still time to influence this decision, pro or con, through the FDA’s public comment portal.